Furthermore, PDGFRα down-regulation by the Shh-I LDE225 in combination with vemurafenib enhances tumor growth inhibition in vitro and in vivo and decreases ERK and AKT activation in both sensitive and resistant cell lines. The gene discussed is PDGFRA; the disease is neoplasm.